Journal
EUROPEAN JOURNAL OF INTERNAL MEDICINE
Volume 82, Issue -, Pages 7-15Publisher
ELSEVIER
DOI: 10.1016/j.ejim.2020.09.025
Keywords
Cardiac amyloidosis; Transthyretin; Grey zones; Disease-modifying therapies; Prognostic stratification
Categories
Ask authors/readers for more resources
Transthyretin amyloid cardiomyopathy (ATTR-AC) is an under-recognized and underdiagnosed disease. Although traditionally considered a rare condition, the epidemiology of the disease is rapidly changing due to the possibility of non-invasive diagnosis through cardiac scintigraphy with bone tracers and novel disease-modifying treatments providing survival advantages. Nevertheless, many questions and grey areas have to be addressed, such as the natural history of ATTR-AC, the role and implications of genotype-phenotype interactions, the best clinical management, prognostic stratification and the most appropriate treatments, including those already recommended for patients with heart failure. Clinicians have to cope with old beliefs and evolving concepts in ATTR-AC. A wide horizon of possibilities for physicians of many specialties is unfolding and awaits discovery.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available